Aurobindo: FDA tentatively approves three-drug pack for HIV-1 infection

By Lisa Kerner

Charlotte, N.C., July 31 - Aurobindo Pharma Ltd. said it has received tentative Food and Drug Administration approval for its combination treatment for HIV-1 infection containing Lamivudine 150 mg and two Zidovudine 300 mg tablets co-packaged with Abacavir 300 mg tablets.

The company said the cost-effective three-drug pack enhances patient convenience and compliance.

According to Aurobindo, the three drugs are leaders in a $600 million market.

Aurobindo is a pharmaceutical company located in Hyderabad, India.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.